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Abstract 
 
Objectives: Post-graduate training for specialisation in psychiatry and psychotherapy is 
part of a 4 to 6 year program. This paper aims to inform on the general situation of 
teaching and training of psychopharmacology-psychopharmacotherapy in Europe. It 
presents the need for a psychopharmacotherapy education in psychiatric training 
programs. Arguments as well as a proposal for a catalogue of learning objectives and an 
outline of a psychopharmacologic curriculum are presented. 
Methods: Based on their experience and on an analysis of the literature, the authors, 
experts in psychopharmacology-pharmacotherapy teaching, critically analyze the present 
situation and propose the development of a curriculum at the European level.  
Results: Teaching programs vary widely between European countries and generally, 
teaching of psychopharmacology and pharmacotherapy does not exceed two-dozen 
hours. This is insufficient if one considers the central importance of psychopharmacology. 
A psychopharmacology-psychopharmacotherapy curriculum for the professional training of 
specialists in psychiatry and psychotherapy is proposed. 
Conclusions: As the number of hours of theoretical teaching and practical training is 
insufficient, a catalogue of learning objectives should be established, which would then be 
part of a comprehensive curriculum at the European level. It could be inspired partly by 
those few previously proposed by other groups of authors and organisms. 
 
 
Keywords: postgraduate training, psychopharmacology-pharmacotherapy-curriculum, residents in 
psychiatry, learning catalogue, Europe  
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1. Introduction 
In most European countries post-graduate training for specialisation in psychiatry and 
psychotherapy is acquired over the course of 4 to 6 year programs (Mayer et al. 2014). In 
the European Union, qualification in one country is recognized within other countries of the 
Union. However, despite efforts to standardize post-graduate training, the curricula in 
different European countries vary greatly. This variability limits comparability between 
countries and international exchange while carrying consequences in the breadth and 
quality of education that trainees receive. We thus conclude that there is a need for 
standardization and possibly regulation of psychiatric education across the EU and are 
proponents of a European certification in resident psychiatric training.  
Studies have demonstrated that, in particular, insufficient time and focus is placed on 
psychopharmacologic training. A recent survey on medical specialization training across 
Europe revealed that all 22 participating countries include training in psychopharmacology 
and pharmacotherapy as part of their psychiatric training programs (Lotz-Rambaldi et al. 
2008). However, a closer look at the situation (using information available by internet 
resources) in some countries such as Austria, France, Germany, Hungary and Switzerland 
shows that postgraduate teaching occurs decentralised and it is organised by individual 
regions. In addition, teaching catalogues are generally rather vague with regard to the 
number of hours of psychopharmacology teaching. Nevertheless, it may be concluded that 
the number of hours declared as psychopharmacology teaching does generally not 
exceed two-dozen hours within in a five-year resident teaching program. We consider this 
amount to be insufficient if one considers the central importance of psychopharmacology 
as a therapeutic tool in psychiatry. On the other hand, there is clearly a lack of data in the 
scientific literature on this important topic. 
In this paper, we propose a standardized European wide curriculum for 
psychopharmacologic training. While we provide insight into the current European 
situation in psychopharmacologic teaching we also argue the benefits of standardizing 
education. Though the proposed curriculum may be a “catalogue of learning objectives” at 
its core, it also includes a detailed statement on its objectives and aims, describes the 
forms of teaching, and informs on the teaching time-plan. Finally, it includes information on 
how teaching and learning should be evaluated.  
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2. Pharmacotherapy of psychiatric patients: Challenges for the treating 
psychiatrist 
Due, in part, to increasing awareness for the relevance of quality of life in psychiatric 
disorders and their treatment, management of psychopharmacotherapy has increasingly 
become a complex and demanding task. Psychiatrists are faced with multiple challenges 
requiring extensive psychopharmacologic knowledge in the strive towards effective, safe, 
and tolerable treatment options for their patients.  
For example, on the one hand, monotherapy of mental diseases represents the generally 
recommended treatment strategy due to associated benefits regarding safety and side 
effects. However, psychiatric comorbidities and poor response to single treatment 
regimens often prompts psychiatrists to prescribe polypharmacy (Blier 2014; Diaz-Caneja 
et al. 2014; Fleischhacker and Uchida 2014; Millan 2014; Moller et al. 2014). For example, 
schizophrenia is associated with high rates of somatic and psychiatric comorbidities such 
as substance abuse (lifetime prevalence: 47%), anxiety, and depressive symptoms 
(estimated prevalence: 15% for panic disorder, 29% for PTSD, 23% for OCD). 
Furthermore, about 50% of schizophrenic patients suffer from comorbid depression 
(Buckley et al. 2009). As a consequence, therapeutic drugs often must be combined in 
order to treat the symptoms of each disorder. Pharmacoepidemiological studies such as 
those performed by the AMSP, the German drug surveillance program, show that more 
than 50 % of patients suffering from schizophrenia are comedicated with 2 antipsychotics. 
25% of inpatients are simultaneously prescribed at least 4 psychotropic drugs (Moller et al. 
2014). However, combination therapy bears the risk of pharmacodynamic and 
pharmacokinetic interactions. Furthermore, the importance of emphasizing monotherapy 
in a teaching curriculum is demonstrated by recent studies suggesting that antipsychotic 
polypharmacy for schizophrenia is frequently overemphasized and that educational 
interventions should stimulate pharmacotherapists to switch from polypharmacy to 
monotherapy (Fleischhacker and Uchida 2014). The current schism between an 
increasing emphasis on the benefits of monotherapy on the one side, with complex 
psychiatric patients and clinical experiences of non-response on the other demonstrates 
the challenges faced by psychiatrists in balancing empiric evidence, clinical experience, 
and the facts of clinical necessity in multimorbid patients. Such hurdles might be 
counteracted using structured, therapeutic decision processes. Such thought processes 
focussed on effective and safe treatment should be conveyed as part of 
psychopharmacologic education as they may serve as essential tools in daily clinical 
practice. 
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In a first step, the treating physician must consider handbooks and summaries of product 
characteristics (SPC) of available drugs. This first step may be limited for some of the 
above-mentioned pathologies, such as substance abuse (cocaine, cannabis, etc.) or 
symptoms of personality disorders, as on-label medications are not available. Next, 
guidelines, which are available for the majority of pathologies and are written by experts, 
most often members of working groups of international (e.g. World Federation of the 
Societies of Biological Psychiatry (WFSBP) (e.g. (Aigner et al. 2011; Hasan et al. 2012; 
Grunze et al. 2013; Hasan et al. 2013) (www.wfsbp.org/educational-activities/wfsbp-
treatment-guidelines-and-consensus-papers.html)) or national scientific societies (e.g. 
(Yatham et al. 2013; Katzman et al. 2014)), should be utilized. However, for difficult to 
treat patients, drugs are frequently recommended in off-label conditions (Baldwin and 
Kosky 2007). This approach may be contradictory to regulations dictated by national drug 
authorities and risks exposing the treating physician to ethical and legal problems. 
Furthermore, on label medications in a particular country qualify as off label in other 
countries and vice versa. As a consequence of globalisation, psychiatrists may practice in 
other countries than in those in which they commenced their training. This is in line with 
the postulate about the free movement of workers throughout Europe (Lotz-Rambaldi et 
al. 2008).  
In addition, genetic and environmental factors responsible for inter-individual differences in 
drug metabolism should be considered in each patient. This pharmacotherapeutic step is 
of increased relevance in polymedicated patients, in which risk of pharmacokinetic 
interactions is higher (Haueis et al. 2011). Placing a focus on drug-metabolism is of 
particular importance in elderly patients and in patients with somatic comorbidities. In this 
regard, therapeutic drug monitoring and particularly pharmacogenetic tests (Kirchheiner et 
al. 2004; Hiemke et al. 2011) may be of interest and great clinical relevance. Furthermore, 
as long term and even lifelong treatments are consistently recommended by guidelines 
and frequently prescribed, treatment must be adapted to changes in comorbidities and 
comedication, as long term treatment is also required in a number of chronic diseases in 
somatic medicine, such as asthma, diabetes mellitus or hypertension. 
The recent developments in psychopharmacotherapy show that many drugs initially 
introduced for a particular pathology, are now also available for the treatment of other 
disorders (e.g. antidepressants for anxiety disorders). As a consequence, the hitherto valid 
classification of psychotropic drugs became obsolete and confusing. This prompted some 
international organizations specialised in psychopharmacology to develop a new 
nomenclature based on 4 axes (pharmacological target and mode of action, approved 
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indications, efficacy and side effects, neurobiology)(Zohar et al. 2013; Zohar et al. 2014). 
This new nomenclature will help the pharmacotherapist to choose an optimal treatment, 
but still requires adequate training in psychopharmacology.  
Likely as a result of the challenges described above, medication errors are frequent. 
However, insufficient teaching in basic sciences including pharmacology is likely to 
increase the risk of such mistakes (Keijsers et al. 2012). An older study revealed that the 
incidence of serious and fatal adverse drug reactions in hospitalized patients was 6.7% 
and 0.32%, respectively, in the USA between 1966 and 1996. According to these 
statistics, fatal adverse drug reactions are between the 4th and 6th leading cause of death 
in the USA. The nature and extent of medication errors varies widely. For example drugs 
other than those prescribed may be administered. Furthermore, wrong dosages, in wrong 
frequencies, at the wrong time may be prescribed.  Patients may miss doses, treatment 
effect and safety monitoring may be deficient, administration may be abruptly 
discontinued, or interacting drugs may be given without sufficient monitoring, which might 
contribute to an increase in the risk of adverse effects (Ito and Yamazumi 2003; Mann et 
al. 2008; Soerensen et al. 2013). Specially designed treatment programs help to reduce 
such errors (Jayaram et al. 2011). As a result, recommendations aiming at preventing 
medication errors by teaching and training have been published (Likic and Maxwell 2009; 
Members of Emerge et al. 2009) and should be emphasized in psychopharmacology 
training. 
Planning, recommendation and prescription of pharmacological treatments also 
represents a challenge for physicians as periodically treatment efficacy in particular of 
antidepressants (Kirsch et al. 2008) is questioned by some groups of authors. On the 
other hand, placebo controlled studies show that differences in clinical efficacy between 
psychotropic drugs and placebo are often low. The validity of such studies is then 
questioned by others (Fountoulakis and Moller 2010). Furthermore, a recent analysis 
revealed that potentially inappropriate prescribing is frequent if physicians experience 
excessive pressure to please patient’s non-medically founded wishes or as a 
consequence of the patient having an inappropriate role in deciding for a most appropriate 
therapy (Cullinan et al. 2014). Physicians may also feel compelled to give preference to 
personal and empirical experience in situations in which they do not find guidelines 
convincing. In situations in which collaboration between the specialist and the general 
practitioner is needed, there may also be fear to communicate critical comments about 
pharmacotherapeutic practices, as not to jeopardise otherwise fruitful cooperation. Such 
conflicts and resulting effects on prescription practices underline that postgraduate 
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psychopharmacological treatment programmes must emphasize pharmacotherapy that is 
appropriate to specific situations, yet respects a patients’ environment. We propose that 
the challenges addressed above may be combated by intense psychopharmacologic 
training. Effective and safe psychopharmacologic treatment requires thorough and 
extensive knowledge on which confident decisions can be based.  
3. Present situation of postgraduate psychopharmacology teaching 
The topic of training in psychopharmacology is rarely addressed in the literature, with the 
exception of the journal Academic Psychiatry, which deals regularly with this important 
subject (Balon 2005; Blanco et al. 2005; Dubovsky 2005; Ellison 2005; Georgiopoulos and 
Huffman 2005; Glick and Zisook 2005; Jefferson 2005; Jibson 2005; Louie et al. 2005; 
Mintz 2005; Osser et al. 2005; Salzman 2005; Weiden and Rao 2005; Zisook et al. 2005; 
Kontos et al. 2006; Zisook et al. 2009; Deligiannidis et al. 2012; Mohr et al. 2012; 
Prabhakar et al. 2012). 
In the USA, a questionnaire was recently sent to 621 general psychiatry residency 
directors. Among the 100 members who responded, 93% replied to have a separate 
psychopharmacology curriculum at their institutions and 90% considered having such a 
curriculum “very important” (Prabhakar et al. 2012). Interestingly, 66% reported that 
teaching comprised more than 30 hours within 4 years of overall training, while only 2% 
devoted less than 10 hours to psychopharmacology. 
There is no overall statistical information available on postgraduate teaching of psychiatry 
and the respective percentages of time and emphasis devoted to psychotherapy and 
psychopharmacology in Europe. Of the 22 European countries that were surveyed, all 
offered structured theoretical training in psychopharmacology, though no details on the 
number of hours dedicated to its teaching were reported (Lotz-Rambaldi et al. 2008). 
Nevertheless, it seems that within 5-year postgraduate teaching programs, about 20 – 40 
hours are typically specifically devoted to theoretical psychopharmacology teaching and a 
similar number of hours are generally dedicated to practically oriented teaching. This 
estimate is based on inquiries in European countries including Austria, Germany, France, 
Hungary and Switzerland. Certainly, courses focused on individual psychiatric pathologies 
and their treatment may emphasize pharmacological treatments within a general treatment 
plan. However, we estimate that the overall percentage of time centred on 
psychopharmacotherapy is not likely to exceed 5 %, while psychotherapy teaching 
frequently exceeds 1000 hours (Laux 2014). For example, in Germany, training in 
psychiatry has undergone important changes and the specialisation is no longer defined 
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as “psychiatry” but as “psychiatry and psychotherapy” (Naber and Hohagen 2008). 
Training includes 100 hours of theoretical courses in psychotherapy, 120 hours of therapy 
in a primary method and 80 hours in a secondary method, in addition to further 
requirements for participation in a comprehensive psychotherapeutic curriculum. In 
contrast, the German system only proves a 40 hour course on basic teaching of 
pharmacological and other biological therapy procedures, in addition to case-related 
advanced training. Clearly, this number of hours dedicated to “classroom teaching” is too 
low, and it should be increased by additional 300 to 400 hours centred on practical 
bedside teaching provided by senior psychiatrists and other experienced colleagues within 
daily clinical practice.  
Literature on psychopharmacology or psychopharmacotherapy teaching and evaluation of 
the clinical practices of psychiatric residents is scarce. A study performed in the USA 
evaluated the practice patterns of psychiatric residents who had achieved postgraduate 
year levels 3 and 4 in their treatment of patients with bipolar disorder. The survey was 
performed in 769 residents, though only 23% replied to the questionnaire. The survey 
revealed that more than a quarter of residents did not initiate treatment with a mood 
stabilizer including lithium, lamotrigine or valproate. Surprisingly, the reason for the lack of 
confidence in prescribing these treatments was due to insufficient opportunity and 
experience in treating bipolar patients (Rakofsky and Dunlop 2012). The authors conclude 
that many residents do not receive adequate training opportunities, but also state that 
there is no clear definition of “adequate training” of pharmacological treatment of bipolar 
patients. These results highlight the necessity of classroom and patient-based teaching to 
foster resident’s confidence in treating patients.  
 
4. Present situation concerning curricula of psychopharmacology 
Several European countries provide catalogues of psychopharmacologic learning 
objectives, but only rather general statements defining the knowledge the candidate must 
acquire before they present for a board examination for specialization are given. These 
exams are generally organised at the country level and, as a result, the programmes are 
often influenced by regional customs or practices at individual institutions. Nationwide 
programmes do not appear to be the rule. Frequently, the content of the programme is 
primarily defined by a few available teachers, who are often specialised in particular fields 
of psychopharmacotherapy. This bears the risk that some issues are not dealt with in 
particular curriculums. Difficulties associated with the lack of a central organizing body are 
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illustrated by the state of psychopharmacologic training in Germany (Laux 2014), in which 
various small regions or even single institutions have unique curricula. It is therefore 
questionable whether each institution is capable of offering comprehensive teaching of all 
relevant domains of psychopharmacotherapy, either because certain fields are not a focus 
of the institution or because teachers from particular fields are not available. Notably, the 
role of “Big Pharma” in teaching postgraduate level psychopharmacology should also be 
considered in this context (Peglow et al. 2014; Riese et al. 2014). A recent European 
study on the interaction between residents in psychiatry and representatives of 
pharmaceutical companies showed that trainees in psychiatry attribute an educational role 
to the pharmaceutical industry (Riese et al. 2014). Furthermore, other authors (Peglow et 
al. 2014) reported that in their hospital, the access to newer drugs is limited and therefore, 
the trainees could not learn from clinical experience, but their knowledge was provided by 
sponsored CME-sessions. These seem to be extreme situations but they, nevertheless, 
demonstrate the importance of structured psychopharmacologic training in order to 
provide well-rounded education independent of the influence of the industry. 
In Germany in 1995, the Association of Neuropsychopharmacology and 
Pharmacopsychiatry (Arbeitsgemeinschaft für Neuropsychopharmakologie und 
Pharmakopsychiatrie; AGNP) previously published a detailed catalogue of learning 
objectives about psychopharmacology education for residents (Breyer-Pfaff et al. 1995a, 
b). Very recently, the working group “Research and Science” from the German Medical 
Director Conference of Psychiatric Hospitals, headed by Gerd Laux, also published a 
proposal for a psychopharmacology curriculum in Germany (Laux 2014). However, most 
other psychopharmacology catalogues of learning objectives or comprehensive curricula 
were published by American medical societies (Prabhakar et al. 2012). The American 
Society of Clinical Psychopharmacology (ASCP) published the 8th edition of the ASCP 
Psychopharmacology curriculum (www.ascpp.org/wp-content/uploads/2012/11/Volume-I-
8th-Edition-TOC-Only-1-23-2015.pdf; 
http://psychopharmcurriculum.com/preview/8thTOC.pdf). The VIIIth edition of the ASCP 
Model Psychopharmacology Curriculum for Training Directors and Teachers of 
Psychopharmacology in Psychiatric Residency Programs includes over 80 lectures in 
PowerPoint format. The material covers a basic course (postgraduate years I and II) and 
in an advanced course (postgraduate years III and IV) plus supplementary lectures. 
Special features have been added, including recommendations of outstanding texts, 
journals, web sites, P450 interactions, algorithms. Pre- and post-test questions are 
available for most lectures in order to help evaluate competency. 
www.ascpp.org/resources/educational-resource/ascp-model-psychopharmacology-
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curriculum-seventh-edition). A sample lecture (Psychopharmacology in the emergency 
room) may be downloaded: http://psychopharmcurriculum.com/preview/Sample.pdf. Other 
curricula, such as “The Psychiatry Milestone Project” developed by the Accreditation 
Council for Graduate Medical Education and The American Board of Psychiatry and 
Neurology 
(https://www.acgme.org/acgmeweb/Portals/0/PDFs/Milestones/PsychiatryMilestones.pdf) 
also outline skills that should be attained during education.   
Therefore, the ASCPP curriculum, which was developed by a committee composed of 
about a dozen well-known authors, represents quite an ambitious work. It may, in fact, be 
considered a gold standard and was utilized as a basis for the European curriculum 
proposed in this paper.  
 
5. Arguments for a curriculum in psychopharmacology in Europe 
As stated by the ASCP committee, the fundamental purpose of such a curriculum is to 
provide a basis for planning and teaching psychopharmacology in a psychiatric residency 
program (Glick et al. 2012). The lack of a European-wide, comprehensive, and 
standardized psychopharmacologic curriculum suggests that psychopharmacologic 
education does not receive necessary focus in psychiatric post-graduate education. The 
lack of a curriculum differentiates psychiatry and psychopharmaology from other medical 
disciplines. Despite experiences made in the USA with the ASCP curriculum, which it is 
more rarely used than expected (Zisook et al. 2009), a curriculum will be valuable as a 
basis for the development of instruments that can be further adapted to individual 
countries or regions.  
On a fundamental level, a well-designed curriculum presents the material that is to be 
taught in a structured and straightforward manner. However, a psychopharmacology 
curriculum would also emphasize the importance of psychopharmacology as an integral 
therapeutic tool in psychiatric practice. On the one hand, this point can be communicated 
in the aims and objectives of the document, which should, as stated above, not only 
consist of a list of learning tools but also underline the curriculum’s focus and goals. In 
addition, the time and energy invested by international experts emphasizes 
psychopharmacology’s relevance and its weight in psychiatric education.  
Harmonization of curricula across regions is essential considering rapidly increasing 
mobility of the academic workforce. Physicians and in particular psychiatrists who migrate 
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within Europe to realise their post-graduate training in psychiatry are of course also 
affected. Many settle in the host country and work either in public institutions or in private 
practice as trained psychiatrists. Standardisation of post-graduate teaching, in this case in 
the field of psychopharmacotherapy would therefore be welcome. 
The patient related benefits of a psychiatric and specifically psychopharmacologic 
curriculum in improving the quality of psychiatric care are evident. A curriculum fosters 
standardization and quality control on multiple levels. Firstly, the quality of education can 
be assessed across various countries, regions, and centres through testing. Secondly, the 
curriculum emphasizes a structured therapeutic decision process, which is likely to 
positively benefit treatment safety. Lastly, the curriculum stresses regular assessment of 
treatment response and drug tolerability, hereby improving patient wellbeing.  
From a trainee point of view, a structured psychopharmacologic curriculum greatly 
improves learning efficiency. Psychopharmacologic practices vary throughout regions, 
centres, and even among mentors, as they are currently strongly influenced by physician 
experience and empirical information. Trainees therefore spend large amounts of time and 
effort sifting through input and comparing learned information to international guidelines. A 
curriculum that emphasizes teaching guideline and evidence-based psychopharmacology 
and ensures that trainees receive this information as a fundament (this may of course be 
supplemented by personal and mentor experience), may circumvent or simplify this step. 
Streamlining of psychopharmacological education therefore also provides more room for 
clinical practice and patient based learning. A curriculum would also foster bilateral 
accountability between institutions and their residents. While residents must fulfil 
curriculum requirements and demonstrate their comprehension of the material, which may 
be assessed through testing, centres are required to provide access to necessary 
expertise either within their staff, or by supporting resident mobility. Furthermore, by 
familiarizing trainees with guidelines and learning resources, a curriculum provides the 
tools necessary for long-term learning across a career. Physicians can therefore adapt 
their practices to the evolving literature, guidelines and recommendations.  
 
6. A curriculum in psychopharmacology-psychopharmacotherapy: proposal 
and a conclusion 
Based on this presentation of the current situation of psychopharmacology teaching at a 
postgraduate level for specialists in psychiatry we concluded that the number of hours of 
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theoretical teaching as well as for practical training is clearly insufficient. It is beyond the 
scope of this paper to propose a detailed learning catalogue and a curriculum. An 
approach in 2 steps is proposed: Firstly, a catalogue of learning objectives should be 
established, which would then be part of a comprehensive curriculum as defined in the 
Introduction. A European curriculum could be inspired partly by those few previously 
proposed by other groups of authors and organisms (Breyer-Pfaff et al. 1995a, b; Glick et 
al. 2012; Prabhakar et al. 2012; Laux 2014). The authors of the present paper propose 
that the curriculum published recently in German by one of us (GL), could be a starting 
point for the development of a European curriculum: Table 1 presents the English version 
of a consensus established in 2014 by the German Medical Director Conference of 
Psychiatric Hospitals (Laux 2014). It comprises the proposal that about 160 hours should 
be dedicated to theoretical teaching, presentations and discussions of case vignettes and 
to CME-quizzes, while an additional about 300 hours should be centered on bedside 
teaching of psychopharmacotherapy. 
Acknowledgements: None 
Statement of interest: None to declare 
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Table 1. Proposal of a Psychopharmacology-Psychopharmacotherapy Curriculum for the 
Professional Training of Specialists in Psychiatry and Psychotherapy 1
14 
 
Theme hours 
I. Basic principles and general pharmacology 38 
1. Pharmacokinetic and pharmacodynamic principles (resorption, distribution, 
metabolism, elimination of pharmaceutical agents; dose-effect relationships; 
assessment of plasma drug levels / therapeutic drug monitoring; receptor 
pharmacology, imaging techniques: fMRT, PET); pharmacogenetics 
6 
2. Neurobiological principles (neurotransmitters, psycho-neuro-endocrinology) 4 
3. Experimental psychopharmacology (animal experimentation, pharmaco-EEG, 
pharmaco-psychology) 
2 
4. Methodology: Clinical studies/trials, assessment of efficacy (statistics; meta-analyses; 
recommended procedures) 
Drug registration processes (in Germany: Institute for Quality and Efficiency in Health 
Care [IQWiG], Federal Joint Committee [G-BA], Act to Reform the Pharmaceutical 
Market [AMNOG]) 
6 
5. Psychopathometry (Rating scales for assessment of mental status) 4 
6. Compliance, doctor-patient relationship, psychoeducation 4 
7. Issues associated with placebo and nocebo effects 2 
8. Side effects/adverse drug reactions (ADRs), intoxications 4 
9. Pharmacological interactions 2 
10. Control investigations, pharmaco-vigilance 4 
  
II. Psychopharmacological agents (general) 6 
1. Definition, classification 1 
2. Overview of the history of psychotropic substances 2 
3. Pharmaco-epidemiology (pharmaceutical agent usage statistics) 2 
15 
 
4. Significance of and attitude to psychopharmacological agents 1 
  
III. Special psychopharmacotherapy 52 
1. Antidepressants 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes, resistance to therapy 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
12 
2. Mood stabilizers 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes, resistance to therapy 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
6 
3. Antipsychotics/Neuroleptics 
• Definition 
• Classification 
• Pharmacology and biochemistry 
8 
16 
 
• Indications 
• Course and duration of therapy, withdrawal syndromes, resistance to therapy 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
4. Tranquilizers/Anxiolytics 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes, resistance to therapy 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
6 
5. Hypnotics 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes, resistance to therapy 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
4 
6. Anti-dementia medications 6 
17 
 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
7. Psychostimulants 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes 
• Side effects and contraindications, interactions 
• Differential indications 
• Specific agents 
• Guidelines 
4 
8. Agents for treatment of withdrawal and dependency 
• Definition 
• Classification 
• Pharmacology and biochemistry 
• Indications 
• Course and duration of therapy, withdrawal syndromes 
• Side effects and contraindications, interactions 
• Differential indications 
4 
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• Specific agents 
• Guidelines 
9. Miscellaneous psychopharmacological agents 
• Agents for treatment of sexual disorders 
• Anti-Parkinsonian agents 
• Anti-epileptic agents 
2 
  
IV. Implementation of psychopharmacotherapy                                                             20 
1. Combination therapies 2 
2. Substance abuse, dependency, withdrawal syndromes 2 
3. Procedures for switching between pharmacological agents 1 
4. Effects of psychopharmacological agents upon general safety and driving ability 1 
5. Psychopharmacological agents during pregnancy and nursing 
Gender-related aspects 
2 
6. Psychopharmacotherapy in aged patients 2 
7. Psychopharmacological agents in child and adolescent psychiatry 3 
8. Trans-cultural aspects (therapy in migrants) 1 
9. Ethical and legal aspects (patient rights, informed consent, off-label prescribing, legal 
responsibility, prescribing guidelines) 
2 
10. Combined pharmaco- and psychotherapy 4 
  
V. Applied psychopharmacotherapy 44 
1. Therapy of acute and chronic organic disorders (delirium, dementia) 4 
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2. Therapy of schizophrenic psychoses and psychotic disorders 4 
3. Therapy of depressive disorders 6 
4. Therapy of bipolar affective disorders 4 
5. Therapy of anxiety and panic disorders 4 
6. Therapy of compulsive disorders 1 
7. Therapy of neurotic, stress-related, and somatoform disorders 2 
8. Therapy of eating and sleep disorders, and of disorders of sexual function 2 
9. Therapy of chronic pain syndromes 1 
10. Therapy of personality and conduct disorders 2 
11. Pharmacotherapy in patients with intellectual deficits 1 
12. Psychopharmacotherapy of ADHD 2 
13. Psychopharmacotherapy in patients with tic and other motor disorders 1 
14. Therapy of withdrawal syndromes and addiction disorders, substitution therapies 2 
15. Emergency psychiatric therapy (agitated states, acute suicidality, acute anxiety and 
panic disorder, delirium) 
6 
16. Pharmaco-economics, cost effectiveness 2 
  
Total 160 
 
1 : Working Group Biological Psychiatry/Science and Research (Head: Gerd Laux) of the 
Conference of Medical Directors of German Hospitals for Psychiatry and Psychotherapy 
[Bundesdirektorenkonferenz - BDK] (cf Laux 2014). 
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